TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16078076

Group type: EXPERIMENTAL
Intervention: Bowel sonography in neonates with NEC (n = 40)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Bowel sonography in healthy neonates (control group, n = 10)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Follow-up examinations in NEC patients (n = 40)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Duration of NPO in group I (echogenic dots)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Duration of NPO in group II (dense granular echogenicities)
Number of subjects: 40
Study: 12194067

Group type: EXPERIMENTAL
Intervention: Partial coherence laser interferometry (PCLI)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional ultrasound biometry
Number of subjects: 100
Study: 9535301

Group type: EXPERIMENTAL
Intervention: Educational program
Number of subjects: 129

Group type: COMPARATOR
Intervention: Control group (no educational program)
Number of subjects: 129
Study: 7808251

Group type: EXPERIMENTAL
Intervention: No-rest group (performed repeated lifts without resting)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Rest group (rested for 30 s between lifts)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (did not train)
Number of subjects: 42
Study: 2520624

Group type: EXPERIMENTAL
Intervention: Morning dose of 40 mg famotidine
Number of subjects: 118

Group type: COMPARATOR
Intervention: Bedtime dose of 40 mg famotidine
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Both morning and bedtime doses of famotidine
Number of subjects: 118
Study: 4741605

Group type: EXPERIMENTAL
Intervention: Mestranol, average daily dose of 23 mug, started within two months of operation
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Mestranol, average daily dose of 23 mug, started three years after oophorectomy
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Mestranol, average daily dose of 23 mug, started six years after oophorectomy
Number of subjects: 114
Study: 28976781

Group type: EXPERIMENTAL
Intervention: Pacifier use (≥4 months)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Control group (no pacifier use)
Number of subjects: 250
Study: 28724351

Group type: EXPERIMENTAL
Intervention: Physical training and nutritional intervention (PTN)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Social support (SOSU)
Number of subjects: 80
Study: 26141511

Group type: EXPERIMENTAL
Intervention: Acamprosate
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo acamprosate
Number of subjects: 100
Study: 24104936

Group type: EXPERIMENTAL
Intervention: Topical corticosteroids
Number of subjects: 247

Group type: COMPARATOR
Intervention: Systemic cyclosporine
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Systemic tacrolimus
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Systemic corticosteroids or cyclosporine
Number of subjects: 247
Study: 22403975

Group type: EXPERIMENTAL
Intervention: 0.075% cetylpyridinium chloride (CPC) + 0.05% sodium fluoride (NaF) in a 6% alcohol base
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: 0.075% cetylpyridinium chloride (CPC) + 0.05% sodium fluoride (NaF) in an alcohol-free base
Number of subjects: 188

Group type: COMPARATOR
Intervention: Control mouthwash containing 0.05% NaF in an alcohol-free base
Number of subjects: 188
Study: 18664702

Group type: EXPERIMENTAL
Intervention: 1 channel compression
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 2 channels compression
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 4 channels compression
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 8 channels compression
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 16 channels compression
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Increasing channel number
Number of subjects: 20
Study: 16533356

Group type: EXPERIMENTAL
Intervention: Folic acid (5 mg/day) and zinc sulphate (66 mg/day)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study: 12713766

Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg plus pravastatin (pooled doses)
Number of subjects: 538

Group type: COMPARATOR
Intervention: Pravastatin alone (pooled doses)
Number of subjects: 538

Group type: COMPARATOR
Intervention: Ezetimibe alone
Number of subjects: 538
Study: 11239753

Group type: EXPERIMENTAL
Intervention: Doctors shown patient questionnaires
Number of subjects: 265

Group type: COMPARATOR
Intervention: Doctors not shown patient questionnaires
Number of subjects: 265
Study: 9691865

Group type: COMPARATOR
Intervention: Magill position
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Manual in-line position
Number of subjects: 20
Study: 7828254

Group type: EXPERIMENTAL
Intervention: Ultrathin fibreoptic laryngoscope (size 1.8 mm OD)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Rigid laryngoscope
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 3411312

Group type: EXPERIMENTAL
Intervention: Counselor A
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Counselor B
Number of subjects: 61
Study: 31511193

Group type: EXPERIMENTAL
Intervention: Absorb BVS
Number of subjects: 1845

Group type: COMPARATOR
Intervention: XIENCE EES
Number of subjects: 1845
Study: 31395420

Group type: EXPERIMENTAL
Intervention: BMP‐2/H (hydroxyapatite soaked with bone morphogenetic protein 2)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Anorganic bovine xenograft
Number of subjects: 25
Study: 29095180

Group type: EXPERIMENTAL
Intervention: Topical vapocoolant spray
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo spray
Number of subjects: 72
Study: 25674830

Group type: EXPERIMENTAL
Intervention: Meaning-based group counseling (MBGC)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control bereavement support group
Number of subjects: 26
Study: 23751021

Group type: EXPERIMENTAL
Intervention: Nonischemic etiology
Number of subjects: 741
Study: 21274853

Group type: EXPERIMENTAL
Intervention: High trajectories of substance initiation
Number of subjects: 2931

Group type: EXPERIMENTAL
Intervention: High aggression trajectory
Number of subjects: 2931

Group type: EXPERIMENTAL
Intervention: Trajectories of delinquency
Number of subjects: 2931

Group type: EXPERIMENTAL
Intervention: Substance use trajectories
Number of subjects: 2931

Group type: EXPERIMENTAL
Intervention: Gender differences
Number of subjects: 2931

Group type: EXPERIMENTAL
Intervention: Ethnic/racial differences
Number of subjects: 2931
Study: 19350630

Group type: EXPERIMENTAL
Intervention: Family history of lung cancer
Number of subjects: 1946

Group type: EXPERIMENTAL
Intervention: Father's history of lung cancer
Number of subjects: 1946

Group type: EXPERIMENTAL
Intervention: Mother's history of lung cancer
Number of subjects: 1946

Group type: EXPERIMENTAL
Intervention: Sibling's history of lung cancer
Number of subjects: 1946

Group type: EXPERIMENTAL
Intervention: Family history of chronic bronchitis
Number of subjects: 1946

Group type: EXPERIMENTAL
Intervention: Family history of pneumonia
Number of subjects: 1946
Study: 17054743

Group type: EXPERIMENTAL
Intervention: Atovaquone-proguanil (AP)
Number of subjects: 255

Group type: COMPARATOR
Intervention: Sulphadoxine-pyrimethamine (SP)
Number of subjects: 255
Study: 15378867

Group type: EXPERIMENTAL
Intervention: 8 cm distal stimulation technique
Number of subjects: 36

Group type: COMPARATOR
Intervention: 3.5 cm distal stimulation technique
Number of subjects: 36
Study: 10982248

Group type: EXPERIMENTAL
Intervention: rhEPO 200 U/kg body weight subcutaneously twice weekly combined with iron sucrose 200 mg intravenously twice weekly
Number of subjects: 12

Group type: COMPARATOR
Intervention: rhEPO 200 U/kg body weight subcutaneously twice weekly combined with iron sulfate 160 mg/day orally
Number of subjects: 12
Study: 9283863

Group type: EXPERIMENTAL
Intervention: Levsin
Number of subjects: 308

Group type: COMPARATOR
Intervention: Glucagon
Number of subjects: 308
Study: 29925680

Group type: EXPERIMENTAL
Intervention: Negative Pressure Treatment (NPT) applied on the sutured wound for one week postoperatively
Number of subjects: 91

Group type: COMPARATOR
Intervention: Traditional dressings used postoperatively
Number of subjects: 91
Study: 27255080

Group type: EXPERIMENTAL
Intervention: Medication-adherence tool intervention
Number of subjects: 25

Group type: COMPARATOR
Intervention: Care as usual (Control)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Baseline questionnaire (Control)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Medication-adherence assessment (Control)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Implementation of the tool (Control)
Number of subjects: 25
Study: 24292489

Group type: EXPERIMENTAL
Intervention: Tamponade
Number of subjects: 100

Group type: COMPARATOR
Intervention: No Tamponade
Number of subjects: 100
Study: 21772309

Group type: EXPERIMENTAL
Intervention: IV tissue plasminogen activator
Number of subjects: 119
Study: 19661244

Group type: EXPERIMENTAL
Intervention: Prednisone 30 mg/d
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 16451406

Group type: EXPERIMENTAL
Intervention: Piperacillin-tazobactam monotherapy
Number of subjects: 763

Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 763

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 763

Group type: EXPERIMENTAL
Intervention: Piperacillin-tazobactam
Number of subjects: 763
Study: 15579793

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: 7.5 microg FSH-CTP
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: 15 microg FSH-CTP
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: 30 microg FSH-CTP
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: 60 microg FSH-CTP
Number of subjects: 55
Study: 11318079

Group type: EXPERIMENTAL
Intervention: Desloratadine 5 mg once daily with azithromycin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fexofenadine 60 mg twice daily with azithromycin
Number of subjects: 0

Group type: COMPARATOR
Intervention: All regimens (desloratadine and fexofenadine with and without azithromycin)
Number of subjects: 0
Study: 9595647

Group type: EXPERIMENTAL
Intervention: COBE Spectra leukoreduction system (LRS)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Standard dual-needle separations
Number of subjects: 89
Study: 7945475

Group type: EXPERIMENTAL
Intervention: Oral methotrexate (MTX)
Number of subjects: 123
Study: 2835890

Group type: EXPERIMENTAL
Intervention: Enalapril 40 mg once daily
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 29274386

Group type: EXPERIMENTAL
Intervention: Structural-lexical approach for auditing SNOMED CT using non-lattice subgraphs and lexical attributes.
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Evaluation of suggested missing IS-A relations by domain experts.
Number of subjects: 200
Study: 28855173

Group type: EXPERIMENTAL
Intervention: Sirukumab 100 mg every 2 weeks
Number of subjects: 1670

Group type: EXPERIMENTAL
Intervention: Sirukumab 50 mg every 4 weeks
Number of subjects: 1670

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1670
Study: 26238278

Group type: EXPERIMENTAL
Intervention: Family Critical Time Intervention (FCTI)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 200
Study: 23137168

Group type: EXPERIMENTAL
Intervention: HPV vaginal self-sampling
Number of subjects: 3767
Study: 21044669

Group type: EXPERIMENTAL
Intervention: 3 doses of PCV-7
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2 doses of PCV-7
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1 dose of PCV-7
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PPV-23
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0 doses of PCV-7 (unvaccinated group)
Number of subjects: 0
Study: 18789766

Group type: EXPERIMENTAL
Intervention: Interferon beta-1a (44 mcg subcutaneous three times per week)
Number of subjects: 764

Group type: COMPARATOR
Intervention: Glatiramer acetate (20 mg subcutaneous once per day)
Number of subjects: 764

Group type: EXPERIMENTAL
Intervention: Interferon beta-1a
Number of subjects: 764

Group type: COMPARATOR
Intervention: Glatiramer acetate
Number of subjects: 764
Study: 16420462

Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 15537482

Group type: EXPERIMENTAL
Intervention: Galantamine 24 mg/day
Number of subjects: 694

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 694
Study: 11333990

Group type: EXPERIMENTAL
Intervention: Individualized counseling aimed at reducing weight, total intake of fat, and intake of saturated fat and increasing intake of fiber and physical activity
Number of subjects: 522

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 522
Study: 9017529

Group type: EXPERIMENTAL
Intervention: Standard Stroop task
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Modified Stroop task with sadness-laden words
Number of subjects: 22
Study: 8318242

Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway
Number of subjects: 28

Group type: COMPARATOR
Intervention: Endotracheal tube
Number of subjects: 28
Study: 3329530

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 526

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 526
Study: 31060522

Group type: EXPERIMENTAL
Intervention: Birth ball use
Number of subjects: 512

Group type: COMPARATOR
Intervention: Usual midwifery care
Number of subjects: 512
Study: 29019365

Group type: EXPERIMENTAL
Intervention: Blueberry supplementation (22.5 g freeze-dried) twice daily for six weeks
Number of subjects: 0
Study: 24365871

Group type: EXPERIMENTAL
Intervention: Remote monitoring system (RMS) intervention for 3 months
Number of subjects: 21

Group type: COMPARATOR
Intervention: Standard discharge instructions (control group)
Number of subjects: 21
Study: 23506636

Group type: EXPERIMENTAL
Intervention: Carvedilol (25.6 ± 12.6 mg daily)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Bisoprolol (5.0 ± 2.4 mg daily)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Nebivolol (5.0 ± 2.4 mg daily)
Number of subjects: 61
Study: 22047610

Group type: EXPERIMENTAL
Intervention: Nutrition education provided to weight loss trial participants
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group not exposed to nutrition education
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 29
Study: 19619218

Group type: EXPERIMENTAL
Intervention: Communication of clinical information to carers as expected by patients and carers
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Communication of clinical information to carers as expected by physicians
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Frequency of information updates as expected by carers
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Frequency of information updates as expected by physicians
Number of subjects: 321
Study: 17326998

Group type: EXPERIMENTAL
Intervention: Transcranial Doppler ultrasound (TCD) measurements in CADASIL patients
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control subjects (age and sex matched)
Number of subjects: 6
Study: 15602250

Group type: EXPERIMENTAL
Intervention: Ice application before injections
Number of subjects: 24

Group type: COMPARATOR
Intervention: No ice application (control)
Number of subjects: 24
Study: 11740143

Group type: EXPERIMENTAL
Intervention: Recombinant FSH (rFSH)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Urinary FSH (uFSH)
Number of subjects: 50
Study: 9143864

Group type: EXPERIMENTAL
Intervention: Phenprocoumon
Number of subjects: 38
Study: 8430199

Group type: EXPERIMENTAL
Intervention: 0.3 mmol/kg gadopentetate dimeglumine
Number of subjects: 199

Group type: COMPARATOR
Intervention: 0.1 mmol/kg gadopentetate dimeglumine
Number of subjects: 199
Study: 3659227

Group type: EXPERIMENTAL
Intervention: H1-antagonist dimethindene (Di) (0.1 mg/kg i.v.)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: H2-antagonist cimetidine (Ci) (5 mg/kg i.v.)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of dimethindene and cimetidine (Di + Ci)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of Ci and Di
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cimetidine (Ci) alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dimethindene (Di) alone
Number of subjects: 0
Study: 31137964

Group type: EXPERIMENTAL
Intervention: Duvelisib (IPI-145)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ofatumumab
Number of subjects: 0
Study: 29024821

Group type: EXPERIMENTAL
Intervention: Outcome Feedback (OF) technology
Number of subjects: 594

Group type: COMPARATOR
Intervention: Control group (no OF technology)
Number of subjects: 594
Study: 25872465

Group type: EXPERIMENTAL
Intervention: 3‐cornered laterally rotated flap (flap 1)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Envelope flap with secondary closure (flap 2)
Number of subjects: 28
Study: 24001154

Group type: EXPERIMENTAL
Intervention: cilostazol (100 mg) plus GBE (80 mg)
Number of subjects: 34

Group type: COMPARATOR
Intervention: cilostazol (100 mg) plus placebo
Number of subjects: 34
Study: 20934771

Group type: EXPERIMENTAL
Intervention: Propofol sedation (70-100 mg/procedure)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Midazolam sedation (3-6 mg/procedure)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Propofol sedation
Number of subjects: 61

Group type: COMPARATOR
Intervention: Healthy controls (no sedation)
Number of subjects: 61
Study: 19559158

Group type: EXPERIMENTAL
Intervention: Literature review on treatment options for osteoporosis in IBD; specific interventions not detailed.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Screening guidelines for osteoporosis in IBD; specific guidelines not detailed.
Number of subjects: 0
Study: 17442410

Group type: EXPERIMENTAL
Intervention: K70E mutation
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: K65R+K70E mutation
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: K65R+K70E+M184V mutations
Number of subjects: 10

Group type: COMPARATOR
Intervention: K65R+K70E
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: K70E
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Double mutant K65R+K70E
Number of subjects: 10
Study: 15447896

Group type: EXPERIMENTAL
Intervention: Biscuit meal (17 g SAG/100 g)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Flakes meal (2 g SAG/100 g)
Number of subjects: 9
Study: 12181217

Group type: EXPERIMENTAL
Intervention: 123I‐MIBG study
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Thallium201 myocardial perfusion study
Number of subjects: 22
Study: 9647493

Group type: EXPERIMENTAL
Intervention: Enalapril (5‐10 mg/day)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Metoprolol (40‐120 mg/day)
Number of subjects: 28
Study: 8004883

Group type: EXPERIMENTAL
Intervention: 25 mg cinnarizine
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: 50 mg cinnarizine
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study: 2547664

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy prior to elective surgery
Number of subjects: 8

Group type: COMPARATOR
Intervention: Chemotherapy and radiotherapy (comparison group)
Number of subjects: 8
Study: 793113

Group type: EXPERIMENTAL
Intervention: Procarbazine and anti-thymocyte serum (ATS) regimen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Procarbazine-ATG-CY
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cyclophosphamide (CY) alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Random donor blood products
Number of subjects: 0

Group type: COMPARATOR
Intervention: Donor or family member transfusions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Second marrow grafts
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: In vitro test for graft rejection prediction
Number of subjects: 0
Study: 31447217

Group type: EXPERIMENTAL
Intervention: Immunoadsorption (IAS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Plasma exchange (PLEX)
Number of subjects: 0
Study: 28816165

Group type: EXPERIMENTAL
Intervention: Proton beam therapy
Number of subjects: 201

Group type: COMPARATOR
Intervention: Intensity modulated radiation therapy (IMRT)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Prior cardiac disease
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Heart volume receiving ≥35 Gy (HV35) >10%
Number of subjects: 201
Study: 26270134

Group type: EXPERIMENTAL
Intervention: High-fat (HF) meal
Number of subjects: 7

Group type: COMPARATOR
Intervention: Low-fat (LF) meal
Number of subjects: 7
Study: 23125444

Group type: EXPERIMENTAL
Intervention: Ad26-EnvA vaccine (10(9) vp, 10(10) vp, 10(11) vp)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ad26-EnvA vaccine (10(11) vp)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ad26-EnvA vaccine (10(9), 10(10), 10(11) vp 3-dose and 10(10) and 5 × 10(10) vp 2-dose groups
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 21526462

Group type: EXPERIMENTAL
Intervention: Telephone-based case management by health care assistants
Number of subjects: 8
Study: 19250788

Group type: EXPERIMENTAL
Intervention: High-performance liquid chromatographic method for quantification of rimonabant in human plasma
Number of subjects: 0
Study: 16627377

Group type: EXPERIMENTAL
Intervention: Orlistat (Xenical) 120 mg 3 times daily
Number of subjects: 3305

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3305

Group type: EXPERIMENTAL
Intervention: Orlistat (Xenical)
Number of subjects: 3305
Study: 15545095

Group type: EXPERIMENTAL
Intervention: 1540-nm Er:glass laser treatment (5 treatments at 6-week intervals)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Maintenance treatments (2 additional treatments at 14 and 20 months)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control group (non-retreated patients)
Number of subjects: 11
Study: 10770196

Group type: EXPERIMENTAL
Intervention: Drug therapy (fenfluramine, 60 mg/day) with energy restriction (−700 Cal/day)
Number of subjects: 40
Study: 9340029

Group type: EXPERIMENTAL
Intervention: Epidural patient-controlled analgesia (PCEA) with bupivacaine 0.25% + sufentanil 2 micrograms/ml (bolus 0.05 ml/kg, lockout 10 min)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Intravenous patient-controlled analgesia (PCA) with morphine (bolus 2 mg, lockout 10 min)
Number of subjects: 62
Study: 8332652

Group type: EXPERIMENTAL
Intervention: Bifrontal (BF) ECT
Number of subjects: 59

Group type: COMPARATOR
Intervention: Bitemporal (BT) ECT
Number of subjects: 59

Group type: COMPARATOR
Intervention: Right Unilateral (RU) ECT
Number of subjects: 59